8th May 2013. Pharma Times. Arricle by Ben Adams.
Barbara Arzymanow, main author of the report said: “The public have been
told that politicians are staying out of the NHS, so this change could seem like hypocritical interference. Patients could mistake value-based pricing for a commitment to make more medicines available, which is not the case. One product can have many uses
and dosage regimes which are of different ‘value’ to different people.
“Pricing of medicines can be improved, but not through this entirely new scheme. The confidence of patients and the
future of medicine are more important than words.”